Pfizer today announced details of a membership agreement with BioMed Central to cover publication costs for research articles published by its researchers.
Pfizer's BioMed Central membership arrangement means that Pfizer will centrally cover the publication fees for any researcher employed or funded by Pfizer when they submit a research article to one of BioMed Central's 190+ peer-reviewed open access journals. By funding open access publication fees in this way, Pfizer aims to make it as straightforward as possible for its researchers to make their research results universally accessible.
Matthew Cockerill, BioMed Central's Managing Director, noted "Many of the world's largest government and private research funders, including the National Institutes of Heath, the Howard Hughes Medical Institute and the Wellcome Trust, have already put in place policies to ensure open access to the results of the their research funding. This new agreement between BioMed Central and Pfizer demonstrates that the pharmaceutical industry also recognizes the benefits of open access."
1. A list of the latest Pfizer-funded research published in BioMed Central's open access journals can be viewed on Pfizer's member page on the BioMed Central website:
2. More than 300 leading research institutions participate in BioMed Central's institutional membership scheme. For more information, see: http://www.
3. BioMed Central (www.biomedcentral.com) is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model. All peer-reviewed research articles published by BioMed Central are made immediately and freely accessible online, and are licensed to allow redistribution and reuse. BioMed Central is part of Springer Science+Business Media, a leading global publisher in the STM sector.